Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center

SHELTON, Conn., Oct. 26, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC (the "Company") announced today that it has extended its agreement with SUNY Upstate Medical Center for further testing of its nanoviricides® drug candidates against varicella-zoster virus (VZV), the shingles virus, that causes debilitating infection of human skin. 

The Company will conduct additional studies in order to finalize the candidates for clinical drug development, and to obtain IND-enabling pre-clinical data, under the extension. The final candidate is expected to undergo toxicology and safety studies leading to IND submission to the FDA for the treatment of shingles in humans.

The Company has previously reported that the nanoviricides® drug candidates showed marked inhibition of VZV infection, replication and spread in human skin cultured ex vivo, over the time course of VZV infection. 

Since VZV causes skin lesions, experimental VZV infection of human skin is considered to be representative of natural VZV infection.  VZV is restricted to human tissue and only infects and replicates in human tissue. Dr. Moffat runs the leading laboratory studying disease-relevant models of VZV infection of human skin for evaluating effectiveness of potential drugs against the shingles virus.

Dr. Moffat is an internationally recognized expert on varicella-zoster virus, and her research has focused on the pathogenesis and treatment of diseases caused by this virus.  The National Institutes of Health has a contract with Dr. Moffat's lab for evaluating anti-viral compounds against VZV.  She is the director of two research core facilities at SUNY Upstate: the Center for Humanized Mouse Models and In vivo Imaging.

About NanoViricides: 
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including VZV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.  Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

View original content with multimedia:http://www.prnewswire.com/news-releases/excellent-results-in-inhibiting-shingles-virus-in-human-skin-nanoviricides-extends-agreement-with-suny-upstate-medical-center-300543762.html

SOURCE NanoViricides, Inc.